| Type 2 Diabetes Mellitus |
1 |
1 |
| Hemoglobin A1c |
0 |
0.8 |
| Hypoglycemia |
0 |
0.8 |
| Blood |
0 |
0.27 |
| Comparative Effectiveness |
0 |
0.27 |
| Weight Management |
0 |
0.26 |
| Metabolism |
0 |
0.18 |
| Receptors |
0 |
0.18 |
| Weight Loss |
0 |
0.18 |
| Healthcare and Medical Technology |
0 |
0.17 |
| Renal Disease |
0 |
0.15 |
| Adverse Effects |
0 |
0.09 |
| Cardiovascular Risk Management |
0 |
0.09 |
| Clinical Research |
0 |
0.09 |
| DPP-4 Inhibitors |
0 |
0.7 |
| Drug Development |
0 |
0.09 |
| Grant |
0 |
0.09 |
| Kidney |
0 |
0.09 |
| Nausea |
0 |
0.09 |
| Patient Safety |
0 |
0.09 |
| SGLT2 Inhibitor |
0 |
0.8 |
| Sulfonylureas |
0 |
0.09 |
| Weight Gain |
0 |
0.09 |